MedinCell Investor Relations Material
Latest events
H2 24/25
MedinCell
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from MedinCell S.A.
Access all reports
MedinCell S.A. is a pharmaceutical company specializing in the development of long-acting injectable therapies using its proprietary BEPO technology. This technology allows for the sustained release of active pharmaceutical ingredients over several days, weeks, or months from a single, bioresorbable injection. The company's portfolio includes products targeting various therapeutic areas, with a focus on treating conditions such as schizophrenia and post-surgical pain. MedinCell collaborates with global pharmaceutical companies and organizations to advance its product pipeline. The company is headquartered in Jacou, France, and its shares are listed on the Euronext Paris.
Key slides for MedinCell S.A.
H2 24/25
MedinCell S.A.
H1 24/25
MedinCell S.A.
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
MEDCL
Country
🇫🇷 France